JR Rahn is the Co-Founder and former Co-CEO, and public head of MindMed, one of the largest public companies in psychedelics.
CV
From his bio on MindMed’s website:
“JR is a former Silicon Valley tech executive who realized that transformational solutions to mental illness and addiction might lie in psychedelic medicines. He spent 2 years researching and began personally investing in psychedelic research through his investment company. JR partnered with drug development veteran Stephen Hurst to start Mindmed in 2019, assembling a leading clinical drug discovery and development team with vast experience conducting clinical trials and research on drug candidates derived from psychedelics. Before starting Mindmed, JR worked in market expansion and operations at Uber. After leaving Uber, he was backed by the Silicon Valley tech accelerator Y Combinator for his company Upgraded. Upgraded is partnered with Apple to provide device financing for Apple customers in Europe.”
Media
- MindMed CEO: Psychedelics to Redefine How Mental Health is Addressed (Investing News, August 2020)
- Episode 5 – JR Rahn Compound Interests with Jon Najarian (Compound Interests, podcast, July 2020)
- JR Rahn – Can we create the “antibiotic of addiction”? (The New Health Club, podcast, July 2020)
- Conversations: JR Rahn, MindMed (Report on Psychedelics, May 2020)
- MindMed’s CEO Jamon “JR” Rahn Wants Nothing To Do With Those Psychedelic Decrim People (Psymposia, May 2020)
- LSD “off-switch” developed by psychedelic pharmaceutical company (New Atlas, April 2020)
Explore more info with a membership (any level)
🧑 Extended profile information
📈 In-depth psychedelic reports (Sprout & Tree)
🪄 Weekly psychedelic research & implementation newsletter (free)